McKesson Corporation (MCK), the pharmaceutical wholesaler reported first quarter sales rose 3% to $27.5 billion from $26.7 billion a year ago. Net income for the quarter rose 3.5% to $298 million or $1.10 per diluted share compared to net income of $288 million or $1.06 per share a year ago.

Merck & Co., Inc (MRK), the drug company reported second quarter sales rose 92% to $11.35 billion from $5.9 billion a year ago. Net income for the quarter fell 52% to $752.4 million or 24 cents per diluted share compared to net income of $1.56 billion or 74 cents per share a year ago.

Amgen Inc (AMGN), the biotechnology company said second quarter revenues rose 2% to $3.8 billion from $3.7 billion a year ago. Net income in the quarter fell 5% to $1.2 billion or $1.25 per diluted share compared to net income of $1.3 billion or $1.25 per share a year ago.

AstraZeneca Plc (AZN), the biopharmaceutical company reported first half revenues rose 7% to $16.8 billion from $15.7 billion a year ago. Net profit for the first half rose 27% to $4.88 billion or $3.36 per diluted share compared to net profit of $3.85 billion or $2.66 per share a year ago.

CONMED Corporation (CNMD), a medical technology company reported second quarter revenues rose 10% to $181.1 million from $164.6 million a year ago. Net income in the quarter rose 418% to $7.31 million or 25 cents per diluted share compared to net income of $1.41 million or 5 cents per share a year ago.

Covance Inc (CVD), the clinical testing company said second quarter revenues rose 2% to $475.2 million from $466.0 million a year ago. Net income in the quarter fell 3% to $31.7 million or 49 cents per diluted share compared to net income of $43 million or 67 cents per share a year ago.

Metabolix, Inc (MBLX), a bioscience company said second quarter revenues fell 67% to $0.1 million from $0.3 million a year ago. Net loss in the quarter was $9.5 million or 36 cents per diluted share compared to net loss of $9.7 million or 42 cents per share a year ago.

Hospira, Inc (HSP), the specialty pharmaceutical and medication delivery company reported second quarter sales rose 1% to $968.2 million from $956.9 million a year ago. Net profit for the quarter rose 227.5% to $83.5 million or 49 cents per diluted share compared to net income of $25.5 million or 16 cents per share a year ago.

United Therapeutics Corporation (UTHR), the biotechnology company reported second quarter revenues rose 64% to $137.5 million from $84 million a year ago. Net income for the quarter was $37.7 million or 62 cents per diluted share compared to net loss of $2.3 million or 4 cents per share a year ago.

Seattle Genetics, Inc (SGEN), the clinical-stage biotechnology company said second quarter revenues rose 293% to $36.9 million from $9.4 million a year ago. Net loss in the quarter was $8.3 million or 8 cents per diluted share compared to net loss of $22.5 million or 26 cents per share a year ago.